1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Alvotech Aiming To Lead Competition On High-Dose Eylea Biosimilar

Icelandic Firm Manufacturing Scale-Up Batches; Follows EU Filing For Aflibercept 2mg

 
• By Dean Rudge

Regeneron’s Eylea 8mg, which offers less frequent dosing and is intended to act as a bulwark against biosimilar competition to the originator’s earlier 2mg version, is a target for biosimilar sponsor Alvotech. The Icelandic firm is aiming to lead the way in global markets.

Business Concept As A Full-Energy Businessman Running On Track To Get Through Red Ribbon As Finish Line. It Means Performing The Best Effort To Succeed The Goal And Overcome Difficulty Ahead.
• Source: Shutterstock

Having only revealed the existence of the biosimilar several months ago, Alvotech is aiming to be the first company to bring a biosimilar to Regeneron’s recently launched high-dose Eylea (aflibercept) 8mg formulation to global markets – a “tremendous opportunity,” the company believes, for both itself and its commercial partners Teva and Advanz Pharma.

“We have developed a formulation and are currently manufacturing scale-up batches, which we believe is in an advanced position

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.